TY  - GEN
AU  - Czuczman,M S
AU  - Leonard,J P
AU  - Jung,S
AU  - Johnson,J L
AU  - Hsi,E D
AU  - Byrd,J C
AU  - Cheson,B D
TI  - Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
SN  - 1569-8041
PY  - 0000///112018///
PB  - Annals of oncology : official journal of the European Society for Medical Oncology
N1  - Publication Type: Journal Article; Published Erratum
UR  - https://doi.org/10.1093/annonc/mdx812
ER  -